NOVEL GENES FOR THE DIAGNOSIS/PROGNOSIS OF BREAST CANCER

用于乳腺癌诊断/预后的新基因

• 批准号: 2422990
• 负责人: JIANGCHUN XU
• 金额: $ 9.99万
• 依托单位: CORIXA CORPORATION
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-30 至 1998-03-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2422990
• 关键词: RNase protection assay; breast neoplasm /cancer diagnosis; breast neoplasms; gene expression; genetic mapping; genetic markers; human genetic material tag; human tissue; molecular oncology; neoplasm /cancer genetics; polymerase chain reaction; prognosis; tissue /cell culture

This proposed discusses the identification, evaluation and development of novel breast cancer markers for the diagnosis and prognosis of human breast.cancer. Breast cancer is second only to long cancer in deaths among women in the U.S. Good prognosis depends ont he early detection of the disease. However, the sensitivity and the specificity of the current available diagnostic markers is not sufficient. Using improved state of the art technology, differential display PCR and the sensitive, specific RT-PCR characterization procedures, we have identified 4 novel breast cancer markers. These novel genes will be further evaluated alone and/or in combination to determine the optimal combination of genes for use in RT-PCR assays and provide the most utility in diagnosis and/or prognosis of breast cancer. Advances have already been achieved at Corixa in identifying these novel cancer markers. This in combination with collaborations with key investigators in he area of breast and prostate cancer and access to an extensive blood and tissue bank should enable the goals and objectives of this proposal to be achieved. PROPOSED COMMERCIAL APPLICATION: The proposed studies will led to commercialization of an RT-PCR assay for diagnosis and?or prognosis of breast cancer. Such tests would be marketed both in the U.S. and worldwide. The estimated world wide market for such a tests is $200-300 million/year.

这项提出的讨论了对的识别，评估和开发 新型乳腺癌标志物用于人类的诊断和预后 乳腺癌。 乳腺癌在死亡中仅次于长期癌症 在美国的妇女中，良好的预后取决于早期发现 疾病。 但是，电流的灵敏度和特异性 可用的诊断标记还不够。 使用改进的状态 艺术技术，差异显示PCR和敏感，特定的 RT-PCR表征程序，我们已经确定了4个新型乳房 癌症标志物。 这些新型基因将单独评估和/或 结合使用以确定基因的最佳组合 RT-PCR分析并提供最大的诊断和/或预后效用 乳腺癌。 在Corixa中已经取得了进步 识别这些新颖的癌症标志物。 这与 与主要调查员在HE乳房和前列腺地区的合作 癌症并获得广泛的血液和组织库应使 要实现的这一建议的目标。 拟议的商业应用：拟议的研究将导致 RT-PCR测定法进行诊断和或预后的商业化 乳腺癌。 此类测试将在美国和 全世界。 此类测试的估计全球市场为200-300美元 百万/年。

项目成果

Detection of circulating tumor cells in peripheral blood of breast cancer patients during or after therapy using a multigene real-time RT-PCR assay.

使用多基因实时 RT-PCR 检测检测乳腺癌患者治疗期间或治疗后外周血中的循环肿瘤细胞。

• DOI: 10.1007/bf03256441
• 发表时间: 2006
• 期刊: Molecular diagnosis & therapy
• 影响因子: 4
• 作者: Zehentner,BarbaraK;Secrist,Heather;Hayes,DawnC;Zhang,Xinqun;Ostenson,RichardC;Loop,Steven;Goodman,Gary;Houghton,RaymondL;Persing,DavidH
• 通讯作者: Persing,DavidH

Application of a multigene reverse transcription-PCR assay for detection of mammaglobin and complementary transcribed genes in breast cancer lymph nodes.

• DOI: 10.1093/clinchem/48.8.1225
• 发表时间: 2002-08
• 期刊: Clinical chemistry
• 影响因子: 9.3
• 作者: B. Zehentner;D. Dillon;Yuqiu Jiang;Jiangchun Xu;Angela Bennington;D. Molesh;Xinqun Zhang;S. Reed;D. Persing;R. Houghton

Mammaglobin as a novel breast cancer biomarker: multigene reverse transcription-PCR assay and sandwich ELISA.

• DOI: 10.1373/clinchem.2004.038687
• 发表时间: 2004-11
• 期刊: Clinical chemistry
• 影响因子: 9.3
• 作者: B. Zehentner;D. Persing;A. Deme;P. Touré;S. Hawes;Lisa Brooks;Q. Feng;Dawn C. Hayes;Cathy W. Critichlow;R. Houghton;Nancy B. Kiviat

Serum antibodies to lipophilin B detected in late stage breast cancer patients.

• 发表时间: 2003-02
• 期刊: Clinical cancer research : an official journal of the American Association for Cancer Research
• 作者: D. Carter;D. Dillon;L. Reynolds;M. Retter;G. Fanger;D. Molesh;P. Sleath;P. Mcneill;T. Vedvick;S. Reed;D. Persing;R. Houghton